Vaxcyte Inc annual ebitda for fiscal TTM was -$1.1 billion, a decrease of 41.8% from -$742 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | ($1.1B) | ($742M) | ($448M) | ($392M) | ($214M) | ($97M) | ($88M) | ($49M) | ($28M) | ($17M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | ($292M) | ($315M) | ($235M) | ($210M) | ($162M) | ($136M) | ($53M) | ($135M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PCVX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All PCVX financial statements → Interactive PCVX charts →
About TickerBase · Data methodology & sources · Privacy · Terms